Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Semin Arthritis Rheum ; 50(3): 503-508, 2020 06.
Article in English | MEDLINE | ID: mdl-31959304

ABSTRACT

Muscular polyarteritis nodosa where disease is isolated to skeletal muscle is a rare and often poorly recognised clinical entity. Patients typically present with fever and severe muscle pain limiting ability to ambulate without rise in creatine kinase. Often there is a significant delay between presentation and diagnosis, which requires histological confirmation. Musculoskeletal MRI is a sensitive investigation that can lead to timely biopsy and improve diagnostic yield. Early diagnosis of this condition is essential as patients typically respond favourably to corticosteroid treatment. Here we report 4 cases of muscular polyarteritis nodosa and review the reported literature.


Subject(s)
Muscle, Skeletal/pathology , Myalgia/etiology , Polyarteritis Nodosa/diagnosis , Adult , Aged , Anti-Inflammatory Agents , Antirheumatic Agents/administration & dosage , Female , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunologic Factors/administration & dosage , Lower Extremity/diagnostic imaging , Male , Methotrexate/administration & dosage , Middle Aged , Muscle, Skeletal/diagnostic imaging , Polyarteritis Nodosa/drug therapy , Polyarteritis Nodosa/physiopathology
2.
Pathology ; 51(5): 518-523, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31230817

ABSTRACT

The role of autoantibody testing for patients with interstitial lung disease is an evolving area. Recent guidelines recommend routine anti-nuclear antibodies, rheumatoid factor, and anti-citrullinated cyclic peptide antibody testing for patients undergoing diagnostic evaluation for interstitial lung disease, with further autoantibody testing reserved for selected cases guided by rheumatological features. Even this approach may miss patients with clinically significant autoantibodies when interstitial lung disease is the dominant or first manifestation of autoimmune disease. We retrospectively performed autoimmune serology in a clinically well characterised cohort of interstitial lung disease patients. Using stored serum, additional testing was performed to ensure all patients had complete autoantibody profiles including anti-nuclear antibodies, extractable nuclear antigen antibodies, double-stranded DNA antibodies, rheumatoid factor, anti-citrullinated cyclic peptide antibodies, anti-neutrophil cytoplasmic antibodies, and myositis antibodies. Eighty patients with interstitial lung disease, and available stored serum, were assessed. Mean age at interstitial lung disease diagnosis was 65.2 years and 42 patients were male. Positive autoimmune serology was found in 56 of 80 (70.0%) patients; the most common positive result was anti-nuclear antibodies (n=34; 42.5%). Myositis antibodies were detected in 13 of 80 (16.2%) patients. Four (5%) patients had elevated anti-citrullinated cyclic peptide antibodies, and two (2.5%) patients had detectable myeloperoxidase antibodies. Eleven (13.7%) patients with negative anti-nuclear antibodies had other significant disease associated autoantibodies. An extended panel of autoantibody testing may detect cases of connective tissue disease associated interstitial lung disease, regardless of clinical or radiological subtype, and prior to extra-pulmonary manifestations of systemic autoimmunity.


Subject(s)
Autoantibodies/blood , Connective Tissue Diseases/complications , Lung Diseases, Interstitial/immunology , Adult , Aged , Aged, 80 and over , Autoimmune Diseases/complications , Autoimmune Diseases/epidemiology , Connective Tissue Diseases/epidemiology , Female , Humans , Male , Middle Aged , Retrospective Studies
3.
Med J Aust ; 210(6): 281-284, 2019 04.
Article in English | MEDLINE | ID: mdl-30838677

ABSTRACT

Pregnancy is known to be a time of increased susceptibility to acquiring to human immunodeficiency virus (HIV) infection and this increased maternal risk places the unborn child at risk of vertical transmission. Pre-exposure prophylaxis (PrEP) involves the provision of antiretroviral therapy to an HIV-negative individual with ongoing risk of HIV exposure to limit the likelihood of HIV transmission. The inclusion of PrEP as part of a comprehensive strategy is recognised as an effective and safe means of reducing HIV infection in serodiscordant couples, thereby reducing the risk of vertical transmission of HIV. Current data suggest that PrEP is safe to continue during pregnancy and breastfeeding in HIV-negative women who remain vulnerable to acquiring HIV. The recent Pharmaceutical Benefits Scheme subsidisation of PrEP has reduced the financial and practical obstacles of PrEP provision, and a subsequent increase in patient awareness and acceptance of PrEP is expected. The framework for appropriately identifying and managing at-risk pregnant and lactating women requiring PrEP is poorly defined and warrants further clarification to better support clinicians and this patient group. This review discusses the current recommendations highlighting the gaps in the guidelines and makes some recommendations for future guideline development.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/prevention & control , Infectious Disease Transmission, Vertical/prevention & control , Pre-Exposure Prophylaxis , Breast Feeding , Female , Humans , Lactation , Practice Guidelines as Topic , Pregnancy
6.
BMC Clin Pathol ; 7: 1, 2007 Mar 02.
Article in English | MEDLINE | ID: mdl-17335577

ABSTRACT

BACKGROUND: Chronic granulomatous disease (CGD) is an inherited disorder of phagocytic cells caused by an inability to generate active microbicidal oxygen species required kill certain types of fungi and bacteria. This leads to recurrent life-threatening bacterial and fungal infections with tissue granuloma formation. CASE PRESENTATION: We describe a case of X-linked Chronic granulomatous disease (CGD) diagnosed in an 18-year-old male. He initially presented with granulomatous disease mimicking sarcoidosis and was treated with corticosteroids. He subsequently developed Burkholderia cepacia complex pneumonia and further investigation confirmed a diagnosis of CGD. CONCLUSION: Milder phenotypes of CGD are now being recognised. CGD should be considered in patients of any age with granulomatous diseases, especially if there is a history of recurrent or atypical infection.

SELECTION OF CITATIONS
SEARCH DETAIL
...